Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthofix adds scorn to Ramius nominees

This article was originally published in Clinica

Executive Summary

Orthopaedics specialist Orthofix International has again raised concerns about the suitability of a potential board member nominated by its disgruntled shareholder Ramius. Orthofix (McKinney, Texas) questioned the nomination of Steven Lee, calling his tenure as president, CEO and chairman of diabetes supplies and service firm PolyMedica into dispute. While Mr Lee was at PolyMedica, the firm was embroiled in two whistleblower lawsuits alleging that the company was involved in fraud and improper reimbursement billing (see Clinica No 1025, p 12). This is the second of Ramius’ board nominations to be criticised by Orthofix – last week the company condemned the nomination of Peter Feld. However, Orthofix did say that it was willing to meet and interview the remaining two board nominees Charles Orsatti and J Michael Egan.

You may also be interested in...



Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals

Topics

UsernamePublicRestriction

Register

MT041532

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel